BLUEBIRD BIO ($BLUE) is expected to release its quarterly earnings data on Tuesday, August 12th before market open, per Finnhub. Analysts are expecting revenue of $46,512,000 and earnings of -$2.64 per share.
You can see Quiver Quantitative's $BLUE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BLUEBIRD BIO Insider Trading Activity
BLUEBIRD BIO insiders have traded $BLUE stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BLUE stock by insiders over the last 6 months:
- RICHARD A COLVIN (Chief Medical Officer) sold 584 shares for an estimated $2,288
- THOMAS J KLIMA (See Remarks) sold 500 shares for an estimated $1,959
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BLUEBIRD BIO Analyst Ratings
Wall Street analysts have issued reports on $BLUE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 03/31/2025
To track analyst ratings and price targets for BLUEBIRD BIO, check out Quiver Quantitative's $BLUE forecast page.
BLUEBIRD BIO Price Targets
Multiple analysts have issued price targets for $BLUE recently. We have seen 2 analysts offer price targets for $BLUE in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $8.0 on 03/31/2025
- Yanan Zhu from Wells Fargo set a target price of $5.0 on 02/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
